sinacell Information

Advancing Regenerative Medicine with Clinical-Grade Stem Cell Solutions Sinacell is an innovative biotechnology company founded in 2007, delivering clinically validated stem cell therapies, tissue engineering solutions, and advanced regenerative medicine technologies to healthcare providers worldwide. Recognized as the first company in Iran to develop and manufacture human amniotic membrane–based biological wound dressings, all Sinacell products are produced in dedicated cleanroom facilities, and the quality control department is also established separately within the cleanroom environment. This ensures that all production and testing procedures are fully compliant with international GMP, IMED, and ISO 13485 standards. Sinacell’s flagship product, Cell-Amniosin, is trusted in clinical practice for advanced wound healing and tissue regeneration. Sinacell’s portfolio includes cell-based medical products, placental and amniotic derivatives, and next-generation biological dressings. The company also provides end-to-end cell therapy services, specializing in the isolation, expansion, and GMP-grade manufacturing of human mesenchymal stem cells (MSCs) and fibroblast cells for clinical and research applications. Driven by strong R&D capabilities, scientific leadership, and clinical collaboration, Sinacell is committed to advancing next-generation therapies and improving patient outcomes worldwide, with all production and quality control activities carried out according to international cleanroom standards to ensure the highest levels of safety and quality.